

Gauntlett, J. C., Dear Doctor Letter, 28 January, 1969.

Hewitt, W. L. and Williams, B., Clinical and Pharmacologic Studies with Chloromycetin, *New England Journal of Medicine*, 242: 119-27, 1950.

Welch, Henry, opening remarks, *Antibiotics Annual*, 1956-7, 1-2, Medical Encyclopedia, Inc., New York, 1957.

CURRICULUM VITAE

Name: William Lane Hewitt, A.B., M.D.

Address: University of California Medical Center, Department of Medicine, Los Angeles 24, Calif.

Birthplace and date: November 25, 1916; Hebron, Nebr.

Education: A.B., University of California, 1938; M.D., University of California, 1942.

Certified: California License, 1942; American Board of Internal Medicine, 1950.

Medical training and appointments: Internship—San Francisco Hospital (City and County), San Francisco, 1941-42; Chief of Medical Officer: U.S. Albireo, (AKA 90), 1943. Staff Member—National Institutes of Health, Bethesda, Md., 1944-45. Assistant Resident and Resident in Medicine, Evans Memorial Hospital, Massachusetts Memorial Hospital, Boston, 1946-48. Visiting Physician—Evans Memorial Hospital, Massachusetts Memorial Hospital, 1948-49. Assistant Professor (in residence), University of California, Los Angeles, 1949-51. Associate Professor of Medicine, University of California, Los Angeles, 1952-58. Professor of Medicine, University of California, Los Angeles, 1958. Chief of Medicine (Acting), Harbor Hospital, Torrance, 1965-66.

Societies: Alpha Omega Alpha; American Board of Internal Medicine; American College of Physicians; American Medical Association; Los Angeles County Medical Association; Los Angeles Society of Internal Medicine; Massachusetts Medical Society; Sigma Xi; Western Association of Physicians; Western Society for Clinical Research; and Infectious Disease Society of America.

Present positions: Professor of Medicine, University of California Medical School, Los Angeles; Attending Specialist, Internal Medicine, Medical Service, Wadsworth General Hospital, Veterans Administration Center, Los Angeles; Associate Consultant in Internal Medicine, Student Health Service, University of California, Los Angeles; Senior Attending Physician, Harbor General Hospital, Torrance; Courtesy Staff, St. John's Hospital, Santa Monica; Consultant Staff, Santa Monica Hospital, Santa Monica; Consultant, Internal Medicine, Veterans Hospital, San Fernando; Anti-Infective Panel Chairman, Drug Efficacy Study, National Academy of Sciences; and Training Program Director, U.S. P.H.S. Graduate Training Grant in Infectious Diseases, UCLA Medical Center and Veterans' Administration Center, Los Angeles.

THE UPJOHN CO.

Kalamazo, Mich., January 28, 1969.

DEAR DOCTOR: Because of misleading and possibly misunderstood statements which have appeared in the lay press, we would like to take this opportunity to clarify our position and to assure you that Panalba remains available.

In the Federal Register of December 24, 1968, the Food and Drug Administration published a notice about Panalba and certain other combination antibiotics. The question is whether certain combinations of drugs should be allowed to remain on the market.

Approximately 40% of the drugs prescribed today are combinations of one form or another. In principle, if the physician's right to prescribe is denied for one category of useful drugs, it is conceivable this same right may be denied for others. We believe the decision as to whether these drugs are used should rest in the hands of the practicing physician.

In accordance with the Federal Register, all interested persons who may be adversely affected by removal of these drugs from the market are invited to comment. Correspondence should be directed to Dr. Paul Bryan, Special Assistant for Drug Efficacy Study Implementation, Bureau of Medicine, Food and Drug Administration, 200 "C" Street, S.W., Washington, D.C. 20204. If you elect to write to Dr. Paul Bryan we, too, would appreciate a copy of your correspondence.

Sincerely,

J. C. GAUNTLETT,
Vice President and Director.